Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 14, 2015 1:32 AM ET

Capital Markets

Company Overview of Skyline Ventures

Company Overview

Skyline Ventures is a venture capital firm specializing in investments in healthcare companies. It typically invests in small molecule and protein therapeutics, medical devices, diagnostics, and technologies that facilitate drug discovery and life science research. The firm primarily invests in companies developing breakthrough medicines that are in or nearing clinical trials; medical devices, where it seeks to fund product development and not research; and startups having intangibles such as proprietary science or engineering or a scientific approach, established leaders, and innovators in the field. It prefers to invest $15 million or more in a portfolio company over the life an investment...

525 University Avenue

Suite 610

Palo Alto, CA 94301

United States

Founded in 1997





Key Executives for Skyline Ventures

Managing Director
Age: 61
Managing Director
Age: 62
Compensation as of Fiscal Year 2015.

Skyline Ventures Key Developments

Skyline Management, LLC Enter into Sublease Agreement with NVP Associates, LLC

On October 10, 2013, Ocera Therapeutics Inc. entered into a sublease with Skyline Management, LLC, as sublandlord (Skyline) for approximately 761 square feet of space in a building located at 525 University Avenue in Palo Alto, California. The Premises are a portion of the space currently leased by Skyline pursuant to a Lease (the Master Lease) by and between Skyline, as tenant, and NVP Associates, LLC, as landlord (NVP). The term of the Sublease will commence on the earlier of October 10, 2013 or the date Ocera Therapeutics Inc. take possession of the Premises, and will end on May 31, 2015. Either Ocera Therapeutics Inc. or NVP may terminate the Sublease prior to the Expiration Date upon four months' written notice. The monthly base rent for the Premises under the Sublease will be equal to the base rent per square foot payable by Skyline pursuant to the Master Lease, which is expected to equal $4.81 per square foot for the remainder of 2013 and $6.30 per square foot beginning on January 1, 2014, multiplied by the square footage of the Premises. If the base rent under the Master Lease increases at any time, the base rent payable under the Sublease will increase in a proportionate amount.

Similar Private Companies By Industry

Company Name Region
G. Research, LLC United States
SRB Diversified Realty, Inc. United States
SAIL Trust II United States
Mosaic Equity L.L.C. United States
vSource 1, Inc. United States

Recent Private Companies Transactions

June 5, 2015
Advion, Inc.
Private Placement
May 26, 2015
SI-Bone Inc.
Private Placement
March 6, 2015
Collegium Pharmaceutical, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Skyline Ventures, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at